Normocalcemic primary hyperparathyroidism: A newly emerging disease needing therapeutic intervention

Hormones

Volumn 11, Issue 4, 2012, Pages 390-396

  Díaz Soto, Gonzalo ^a   Julián, María Teresa ^b   Puig Domingo, Manel ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Asymptomatic; Hyperparathyroidism; Normocalcemic

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ASYMPTOMATIC DISEASE; BONE DENSITY; BONE MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DYSLIPIDEMIA; FRAGILITY FRACTURE; HUMAN; HYPERCALCIURIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; NEPHROLITHIASIS; NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; REVIEW; SYMPTOMATOLOGY;

EID: 84872053789     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1370     Document Type: Review

References (36)

1. Silverbeng SJ, Bilezikian JP, 2003 "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 88: 5348-5352.
2. Bilezikian JP, Khan A, Potts JT, 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94: 335-339.
3. Carneiro-Pla D, Solorzano C, 2012 A summary of the new phenomenon of normocalcemic hyperparathyroidism and appropriate management. Curr Opin Oncol 24: 42-45.
4. Wills MR, Pak CY, Hammond WG, Bartter FC, 1967 Normocalcemic primary hyperparathyroidism. Am J Med 47: 384-391.
5. Monchik JM, Gorgun E, 2004 Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 136:1242-1246.
6. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR, 2009 Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94: 351-365.
7. Bilezikian JP, Silverbeng SJ, 2010 Normocalcemic pri may hyperparathyroidism. Arq Bras Endocrinol Metab 54: 106-109.
8. Eastell R, Arnold A, Brandi ML, et al, 2009 Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 94: 340-350.
9. Souberbielle JC, Cormier C, Kindermans C, et al, 2001 Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86: 3086-3090.
10. Looker AC, Pfeiffer CM, Lacher, DA, et al, 2008 Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 88: 1519-1527.
11. Chapuy MC, Arlot ME, Duboeuf F, et al, 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: 1637-1642.
12. Chapuy MC, Pamphile R, Paris E, et al, 2002 Combined calcium and vitaminD3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13: 257-264.
13. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, 1997 Effect of calcium and vitamin supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670-676.
14. Harvey A, Hu M, Gupta M, et al, 2011 A New, Vitamin D-Based, Multidimensional Nomogram for the Diagnosis of Primary Hyperparathyroidism. Endocr Pract 8: 124-131.
15. Lundgren E, Hagstrom EG, Lundin J, et al, 2002 Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population based screening 8 yrs ago. World J Surg 226: 931-936.
16. Maruani G, Hertig A, Paillard M, Houillier P, 2003 Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88: 4641-4648.
17. Tordjman KM, Greenman Y, Osher E, et al, 2004 Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117: 861-863.
18. Lowe H, McMahon DJ, Rubin MR, et al, 2007 Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92: 3001-3005.
19. Hagström E, Lundgren E, Rastad J, Hellm P, 2006 Metabolic abnormalities in patients with normocalcemia hyperparathyroidism detected at a population-based screening. Eur J Endocrinol 155: 33-39.
20. Hedbäck G, Odén A, 1998 Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Invest 28: 1011-1018.
21. Valdermarsson S, Lindblom P, Bergenfelz A, 1998 Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Interm Med 244: 241-249.
22. Hedbäck G, Odén A, 1998 Increased risk of death from primary hyperparathyroidism-an update. Eur J Clin Invest 28: 271-276.
23. Jorde R, Sundsfjord J, Fizgerald P, Bonaa HK, 1999 Serum calcium and cardiovascular risk factors and diseases: the Tromsö study. Hypertensión 34: 484-490.
24. Jorde R, Bonaa KH, Sundsfjord J, 1999 Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure: the Tromsö study. Eur J Endocrinol 141: 350-357.
25. Adams JS, Hewison M, 2010 Update in vitamin D. J Clin Endocrinol Metab 95: 471-478.
26. Tordjam KM, Yaron M, Izkhakov E, et al, 2010 Cardiovascular risk factors and arterial rigidity in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol 162: 925-933.
27. Udelsman R, Pasieka JL, Sturgeon C, Young JEM, Clark OH, 2009 Surgery for Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J Clin Endocrinol Metab 94: 366-372.
28. Carneiro-Pla DM, Romaguera R, Nadji M, Lew JI, Solorzano CC, Irvin GL 3rd, 2007 Does histopathology predict parathyroid hypersecretion and influence correctly the extent of parathyroidectomy in patients with sporadic primary hyperparathyroidism? Surgery 142: 930-935.
29. Soto GD, Halperin I, Squarcia M, Lomeña F, Domingo MP, 2010 Update in thyroid imaging. The expanding world of thyroid imaging and its translation to clinical practice. Hormones (Athens) 9: 287-298.
30. Wade TJ, Yen TW, Amin AL, Wang TS, 2012 Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36: 761-766.
31. Goldfarb M, Gondek S, Irvin GL 3rd, Lew JI, 2011 Normocalcemic parathormone elevation after successful parathyroidectomy: long-term analysis of parathormone variations over 10 years. Surgery 150: 1076-1084.
32. Beyer TD, Solorzano CC, Prinz RA, Babu A, Nilubol N, Patel S, 2007 Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery 141: 777-783.
33. Khan AA, Bilezikian JP, Potts JJ, 2009 Asymptomatic primary hyperparathyroidism: a Commentary on the revised guidelines. Endocr pract 15: 494-498.
34. Khan AA, Bilezikian JP, Kung AW, 2004 Aleudronate in primary hyperparathyroidism: a doubleblind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 3319-3325.
35. Marcocci C, Cetani F, 2012 Update on the use of cinacalcet in the management of primary hyperparathyroidism. Endocrinol Invest 35: 90-95.
36. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM, 2005 Cinacalcethydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135-141.